NCT00782327 is a Phase 3 clinical trial of Losartan in Marfan Syndrome, sponsored by University Hospital, Ghent.

Who is sponsoring NCT00782327?

NCT00782327 is sponsored by University Hospital, Ghent.

What drugs are being tested in NCT00782327?

Interventions in NCT00782327: Losartan, Placebo.

What condition does NCT00782327 study?

NCT00782327 studies Marfan Syndrome.

Is NCT00782327 still recruiting?

NCT00782327 is currently completed. Last updated 22 December 2022.

Last reviewed 2022-12-22 · How we verify

NCT00782327

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Randomized, Double-blind Study for the Evaluation of the Effect of Losartan Versus Placebo on Aortic Root Dilatation in Patients With Marfan Syndrome Under Treatment With Beta-blockers

Completed Phase 3 Last updated 22 December 2022

What this trial tests

Phase 3 trial testing Losartan in Marfan Syndrome in 22 participants. Completed in 26 November 2014.

Timeline

1 November 2009

Primary endpoint
26 November 2014

26 November 2014

Quick facts

Lead sponsor	University Hospital, Ghent
Phase	Phase 3
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	treatment
Enrollment	22
Start date	1 November 2009
Primary completion	26 November 2014
Estimated completion	26 November 2014
Sites	1 location across Belgium

Drugs / interventions tested

Losartan (losartan) — full drug profile →
Placebo

Conditions studied

Marfan Syndrome — all drugs for Marfan Syndrome →

Sponsor

University Hospital, Ghent

Who can join

10 and older, any sex, with Marfan Syndrome. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

To study the effect of losartan (an angiotensin receptor blocker-ARB) on aortic root growth in patients with Marfan syndrome, already treated with beta-blockers (BB). The effect of losartan will be compared to placebo. Losartan or placebo will be added to the treatment regimen in a two-step up-titration scheme over 2 weeks. Start doses of Losartan will be 25 mg for subjects under 50kg of weight and 50mg if the weight is over 50kg. Uptitration will be guided by the tolerance of the drug by the patients. Patients will be contacted by phone call for assessment of side-effects before second step of uptitration. Daily maximal doses of Losartan will be 50mg for subjects under 50kg of weight and 100mg if the weight is over 50kg

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Targeting the TGFβ signalling pathway in disease.
Akhurst RJ, Hata A. · · 2012 · cited 1225× · PMID 23000686 · DOI 10.1038/nrd3810
Medical treatment of aortic aneurysms in Marfan syndrome and other heritable conditions.
Attenhofer Jost CH, Greutmann M, Connolly HM, Weber R, et al · · 2014 · cited 24× · PMID 24527681 · DOI 10.2174/1573403x1002140506124902
Preventing the aortic complications of Marfan syndrome: a case-example of translational genomic medicine.
Li-Wan-Po A, Loeys B, Farndon P, Latham D, et al · · 2011 · cited 4× · PMID 21276043 · DOI 10.1111/j.1365-2125.2011.03929.x

Verify or expand the search:

Other trials of Losartan

Trials testing the same drug.

NCT06491940 — Comparison of the Role of Losartan Alone vs Hydrochlorothiazide Plus Losartan · NA · not yet recruiting
NCT06333522 — Losartan Use to Mitigate Arthrofibrosis Following Total Joint Arthroplasty · Phase 4 · withdrawn
NCT06150560 — A Study of Angiotensin-II Receptor Blocker on Cardiovascular Remodeling (VALUE Trial) · Phase 3 · recruiting
NCT06108063 — Mitigation of Arthrofibrosis After Total Knee Arthroplasty Using Losartan · Phase 1, PHASE2 · recruiting
NCT06329050 — The Effects of Losartan on Attention Control: An Eye-tracking Study · NA · recruiting

Other recruiting trials for Marfan Syndrome

Currently open trials in the same condition.

NCT06546137 — National Network for Cardiovascular Genomics: Advancing Cardiovascular Healthcare for Hereditary Diseases in Brazil's Un · recruiting
NCT05809323 — Marfan Syndrome Moderate Exercise Trial II · NA · recruiting
NCT04970459 — Biological Collection for Marfan and Related Syndromes · recruiting
NCT03440697 — Pathogenetic Basis of Aortopathy and Aortic Valve Disease · active not recruiting

Other University Hospital, Ghent trials

Trials by the same sponsor.

NCT07584486 — Development of a New Simplified Tool to Predict LNPCPs Histology and Assess the Risk of Submucosal Invasive Cancer. The · NA · not yet recruiting
NCT07327450 — Coaching Doctors and Nurses to Improve Ethical Decision-making in Team · NA · not yet recruiting
NCT07402057 — Implementation and Evaluation of a Program Aimed at Facilitating Palliative Care Conversations · NA · recruiting
NCT07387328 — Validation of New sEMG Electrode Placement Guidelines for the Triceps Surae in Post-stroke Individuals. · not yet recruiting
NCT07237399 — Percutaneous Thermo-ablation for the Treatment of Prostate Cancer Oligometastatasis (TA-P-OLIM) · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00782327 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University Hospital, Ghent
Last refreshed: 22 December 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00782327.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing